GlassScriptPhysician profile
Aji Mathew
NPI 1538713599
$3,340.17
in general payments reported to CMS, 2019-2025
21 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $335 · 2023: $572 · 2024: $1,002 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.06 |
| Education | $206.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $395.58 | 2021-2025 | Jakafi |
| Astellas Pharma US INC | $388.39 | 2023-2025 | Cresemba, Xospata |
| Novartis Pharmaceuticals Corporation | $331.53 | 2022-2025 | |
| Sobi, INC | $294.82 | 2022-2025 | |
| Celgene Corporation | $280.57 | 2021-2025 | Reblozyl, Breyanzi |
| Astrazeneca Pharmaceuticals LP | $263.75 | 2022-2025 | Calquence |
| Glaxosmithkline, LLC. | $236.61 | 2024-2025 | Ojjaara |
| Syndax Pharmaceuticals, INC. | $236.04 | 2025 | |
| Abbvie INC. | $167.94 | 2021-2025 | |
| Pfizer INC. | $137.41 | 2024 | |
| Lilly USA, LLC | $133.56 | 2023-2025 | Jaypirca |
| Janssen Biotech, INC. | $117.42 | 2021-2024 | Imbruvica |
| Mirati Therapeutics, INC. | $113.63 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $54.83 | 2024-2025 | Iclusig |
| Adaptive Biotechnologies Corporation | $41.67 | 2022-2024 | Clonoseq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $35.04 | 2025 | |
| Rigel Pharmaceuticals, INC. | $26.57 | 2024 | Tavalisse, Rezlidhia |
| Amgen INC. | $25.90 | 2022 | |
| Servier Pharmaceuticals LLC | $24.62 | 2022 | |
| Invivyd INC | $18.80 | 2024 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $15.49 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aji Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.